A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis

NCT05006352 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG: DNL343
DRUG: Placebo

Sponsor

Denali Therapeutics Inc.